-
The total response rate exceeds 60% for recurrent cancer! Innovative bispecific antibodies were given priority review
Time of Update: 2023-01-05
Epcoritamab is a subcutaneously administered CD20/CD3 bispecific antibodyThe application submitted is based on the previously published EPCORE Results of the NHL-1 open-label, multicenter Phase 1/2 clinical trial.
-
Cell Stem Cell, a scholar from the Chinese Academy of Sciences, released a specially invited review of "Mesenchymal Stem Cell and Immune Response Interaction"
Time of Update: 2022-11-14
On November 3, 2022, Cell Stem Cell, an internationally renowned stem cell academic journal, published an invited review written online by researcher Wang Ying and Professor Shi Yufang of the Shangha
-
Science provides "quality assurance" for new stem cells: macrophages are responsible for review
Time of Update: 2022-09-30
”Quality assurance of hematopoietic stem cells by macrophages determines stem cell clonality The top two images show a stressful stem cell, shown by the calreticulin (yellow spike) expressed on its surface, which is engulfed and engulfed by macrophages.
-
"Scientific review of probiotic 'dose-response relationship'" released
Time of Update: 2022-09-04
In 2021, the Probiotics Branch of the Chinese Society of Food Science and Technology formally established the research project "Scientific Review of Probiotics' Dose-Effect Relationship", with a view to providing technical reference for the health effect, dosage index and industrial application of probiotics in China's standard regulations .
-
Heavyweight "Scientific Review of Probiotic 'Dose-Response Relationship'" Released
Time of Update: 2022-08-19
In 2021, the Probiotics Branch of the Chinese Society of Food Science and Technology formally established the research project "Scientific Review of Probiotics' Dose-Effect Relationship", with a view to providing technical reference for the health effect, dosage index and industrial application of probiotics in China's standard regulations .
-
Zhu Yingfang's research group published a review paper on plant stress responses in Trends in Plant Science
Time of Update: 2022-01-23
Zhu Yingfang from Henan University were invited to jointly write a review of mass spectrometry research technology related to plant stress response research.
-
Nature Immunology Cao Xuetao was invited to write a review on the inflammatory response prone to new coronavirus infections
Time of Update: 2021-11-04
Editor’s note iNature is China’s largest academic official account. It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units
-
Third review of the "Physician Law" draft: suggest that doctors should be exempted from responsibility for saving lives outside the hospital
Time of Update: 2021-09-04
Carefully read the "Physician Law (Draft Second Review)", which contains provisions to encourage and support doctors saving people outside the hospital.
-
Nature's in-depth review: Improving cancer immunotherapy targeted DNA damage response is promising
Time of Update: 2021-08-26
The review authors pointed out that, overall, a number of independent early clinical trials have shown that the combination of DDR-targeting therapies and immune checkpoint inhibitors is safe and has shown encouraging anti-cancer efficacy .
-
New immunotoxin! Vicinium treatment of high-risk BCG non-response bladder cancer (NMIBC) EU
Time of Update: 2020-05-08
May 08, 2020 / BioValley BIO/ -- SeenBio is a late-stage, clinical biopharmaceutical company focused on developing targeted fusion protein therapies for cancer Recently, the company announced that
-
The first neurofibromatosis type 1 treatment drug! AstraZeneca / selumetinib obtained FDA priority review, with a total response rate of 66%
Time of Update: 2019-11-15
November 15, 2019 / BIOON / -- AstraZeneca, a British pharmaceutical giant, and Merck & Co, a partner, recently announced that the US Food and Drug Administration (FDA) has accepted and granted priori